VRNA - ベロナ・ファ―マ (Verona Pharma plc) ベロナ・ファ―マ

 VRNAのチャート


 VRNAの企業情報

symbol VRNA
会社名 Verona Pharma Plc (Adderbury) (ベロナ・ファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種    医療関連(Health Care)
概要 事業概要 --   ベロナ・ファ―マはイギリスの製薬会社。主に慢性呼吸器疾患の治療用医薬品の開発・商品化に従事する。主に慢性閉塞性肺疾患(COPD)、ぜんそく、咳などの治療に焦点を当て、同社開発中の新薬は「RPL554」、「VRP700」と「NAIPs」の3種類を含む。本社所在地は英国ウェ―ルズ・カ―ディフ。   Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma's product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE ('Ensifentrine as a Novel inHAled Nebulized COPD thErapy') for COPD maintenance treatment. The Company raised gross proceeds of $200 million through a private placement in July 2020 and expects the funds to support its operations and Phase 3 clinical program into 2023. Two additional formulations of ensifentrine are currently in Phase 2 development for the treatment of COPD: dry powder inhaler ('DPI') and pressurized metered-dose inhaler ('pMDI'). Ensifentrine is being evaluated in a pilot clinical study in patients hospitalized with COVID-19 and has potential applications in cystic fibrosis, asthma and other respiratory diseases.
本社所在地 One Central Square Cardiff CF10 1FS GBR
代表者氏名
代表者役職名
電話番号
設立年月日 38384
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数 7人
url www.veronapharma.com/
nasdaq_url https://www.nasdaq.com/symbol/vrna
adr_tso 9182592
EBITDA EBITDA ー
終値(lastsale) 12.93
時価総額(marketcap) 118730914.56
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 VRNAのテクニカル分析


 VRNAのニュース

   Verona Pharma Insider Trades $325K In Company Stock  2021/11/04 15:28:28 Benzinga
David Zaccardelli , President And CEO at Verona Pharma (NASDAQ: VRNA ), made a large insider sell on November 2, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that Zaccardelli sold 506,904 shares of Verona Pharma at a price of $0.64. The total transaction amounted to $324,476. Following the transaction, Zaccardelli still owns 16,845,352 shares of Verona Pharma worth $87,932,737. Verona Pharma shares are trading up 2.15% at $5.22 at the time of this writing on Thursday morning. Now trade stocks online commission free with Full story available on Benzinga.com
   Verona Pharma Announces November 2021 Investor Conference Participation  2021/11/01 07:00:00 Intrado Digital Media
LONDON and RALEIGH, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present at the following investor conferences in November 2021:
   Asthma & COPD Market Overall Study Report 2021-2028 | AstraZeneca, Novartis AG, GlaxoSmithKline plc, Merck & Co., Verona Pharma plc,  2021/10/27 13:46:09 OpenPR
Asthma is a lung disease that affects millions of people worldwide. Breathing problems, chest pain, coughing, and wheezing are also possible symptoms. The global asthma and COPD market is expected to account around US$ 30,710.2 Mn in terms of value in
   Verona Pharma to Report Third Quarter 2021 Financial Results and Provide Corporate Update  2021/10/26 06:00:00 Intrado Digital Media
LONDON and RALEIGH, N.C., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the three and nine months ended September 30, 2021 on Tuesday, November 9, 2021 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.
   Verona Pharma to Present Phase 2 Data with pMDI Ensifentrine in COPD at CHEST 2021  2021/10/13 06:00:00 Benzinga
LONDON and RALEIGH, N.C., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ: VRNA ) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the presentation of Phase 2 data demonstrating the positive effect of a pressurized metered-dose inhaler ("pMDI") formulation of ensifentrine in patients with moderate to severe chronic obstructive pulmonary disease ("COPD") at CHEST Annual Meeting ("CHEST") 2021 taking place on October 17-20. The data are published in the CHEST Annual Meeting on-line supplement. Data from Part B of the two-part study, first reported on February 2, 2021 , showed ensifentrine delivered by pMDI over one week provided statistically significant, clinically meaningful and dose-dependent improvements in lung function and was well tolerated with an adverse advent profile similar to placebo. The data are consistent with results for dry powder inhaler ("DPI") and nebulizer formulations of ensifentrine. Ensifentrine is an investigational, first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 ("PDE3" and "PDE4").
   Verona Pharma : 2021 AGM Notice and Proxy Statement | MarketScreener  2021/03/21 11:05:02 MarketScreener
Verona Pharma plc NOTICE & PROXY STATEMENT Annual General Meeting of Shareholders April 27, 2021 1:00 p.m. … | March 21, 2021
   Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference | MarketScreener  2021/03/01 07:00:02 MarketScreener
LONDON and RALEIGH, N.C., March 01, 2021 -- Verona Pharma plc , a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive… | March 1, 2021
   Verona Pharma Earnings and Growth Analysis : Stock market Insights & financial analysis  2021/02/25 07:04:00 Stock Market Daily
Verona Pharma announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update - Stocks News Feed  2021/02/18 07:00:00 Stocks News Feed
LONDON and RALEIGH, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) — Verona Pharma plc (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the fourth quarter and full year ended December 31, 2020 on Thursday, February 25, 2021 and host an investment community conference call… Read More »Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
   Financial Comparison: Zosano Pharma (NASDAQ:ZSAN) and Verona Pharma (NASDAQ:VRNA)  2021/02/12 10:57:23 Modern Readers
Zosano Pharma (NASDAQ:ZSAN) and Verona Pharma (NASDAQ:VRNA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership. Valuation & Earnings This table compares Zosano Pharma and Verona Pharma’s top-line revenue, earnings per […]

 関連キーワード  (― 米国株 ベロナ・ファ―マ VRNA Verona Pharma plc)

 twitter  (公式ツイッターやCEOツイッターなど)